Candriam S.C.A. I Mab Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMAB
# of Institutions
36Shares Held
15.5MCall Options Held
56.4KPut Options Held
5.8K-
Hhlr Advisors, Ltd. Grand Cayman, E96.91MShares$7.39 Million0.2% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$4.46 Million3.04% of portfolio
-
Boothbay Fund Management, LLC New York, NY1.42MShares$1.52 Million0.05% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U0567KShares$606,3150.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny499KShares$534,2510.0% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $88.9M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...